Abstract
In sepsis death follows an excessive inflammatory response involving cytokines and complement that is activated primarily via the amplifying C3/C5 convertase. Excessive stimulation of complement amplification requires IgG-containing or F(ab′)2-containing immune complexes (IC) that capture dimeric C3b on one of their heavy chains or heavy chain fragments. The ability of IgG-IC to capture dimeric C3b by the Fab portion is dependent on an affinity for C3 within the Fab portion, but outside the antigen-binding region. This property is rare among IgG NAbs. In contrast to this, the lack of the Fc portion renders the Fab regions of any F(ab′)2-IC accessible to nascent C3b, but dimeric C3b deposits only if F(ab′)2-IC form secondary IC with anti-hinge NAbs that rigidify the complex and thereby promote deposition of dimeric C3b. Both types of complexes, C3b2-IgG-IC and C3b2-F(ab′)2-IC/anti-hinge NAbs, are potent precursors of alternative C3 convertases and stimulate complement amplification along with properdin up to 750 times more effectively than C3b and properdin. F(ab′)2 fragments are not normally generated, but are formed from NAbs by enzymes from pathogens and neutrophils in sepsis. Unlike IgG-IC F(ab′)2-IC are not cleared by Fc-receptor dependent processes and circulate long enough to form secondary IC with anti-hinge NAbs that rigidify the complexes such that they capture dimeric C3b and gain the potency to stimulate complement amplification.
Chapter PDF
Similar content being viewed by others
Keywords
- Severe Sepsis
- Immune Complex
- Alternative Complement Pathway
- Glutamyl Endopeptidase
- Neutrophil Elastase Inhibitor
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Weiser MR, Williams JP, Moore FD et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183:2343–8. PMID:8642343 doi:10.1084/jem.183.5.2343
Stahl GL, Xu Y, Hao L et al. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 2003; 162:449–55. PMID:12547703 doi:10.1016/S0002-9440(10)63839-4
Lutz HU, Fumia S. Stimulation of complement amplification by F(ab′)2-containing immune complexes and naturally occurring anti-hinge antibodies, possible role in systemic inflammation. Autoimmun Rev 2008; 7:508–13. PMID:18558371 doi:10.1016/j.autrev.2008.04.017
Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4:133–42. PMID: 15040586 doi: 10.1038/nri1269
Ratnoff WD, Fearon DT, Austen KF. The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol 1983; 6:361–71. PMID:6364431 doi:10.1007/BF02116280
Lutz HU, Nater M, Stammler P. Naturally occurring anti-band 3 antibodies have a unique affinity for C3. Immunology 1993; 80:191–6. PMID:8262548
Lutz HU, Stammler P, Fasler S. Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. J Biol Chem 1993; 268:17418–26. PMID:8349625
Jelezarova E, Vogt A, Lutz HU. Interaction of C3b2-IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem J 2000; 349:217–23. PMID: 10861231 doi:10.1042/0264-6021:3490217
Nelson B, Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol 1979; 122:1994–9. PMID:376729
Schenkein HA, Ruddy S. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for zymosan enhances alternative pathway activation by zymosan. J Immunol 1981; 126:7–10. PMID:6778918
Gadd KJ, Reid KBM. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J 1981; 195:471–80. PMID:7316962
Lucisano Valim YML, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes-a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 1991; 84:1–8. PMID: 1707767 doi:10.1111/j.1365-2249.1991.tb08115.x
Banda NK, Wood AK, Takahashi K et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum 2008; 58:3081–9. PMID:18821684 doi:10.1002/art.23865
Jelezarova E, Luginbuehl A, Lutz HU. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation. J Biol Chem 2003; 278:51806–12. PMID:14527961 doi:10.1074/jbc.M304613200
Gadd KJ, Reid KB. Importance of the integrity of the inter-heavy-chain disulphide bond of rabbit IgG in the activation of the alternative pathway of human complement by the F(ab′)2 region of rabbit IgG antibody in immune aggregates. Immunology 1981; 42:75–82. PMID:6780451
Reid KB. Complement fixation by the F(ab′)2-fragment of pepsin-treated rabbit antibody. Immunology J 1971; 20(5):649–58. PMID:5006125
Sissons JG, Cooper NR, Oldstone MB. Alternative complement pathway-mediated lysis of measles virus infected cells: induction by IgG antibody bound to individual viral glycoproteins and comparative efficacy of F(ab′)2 and Fab′ fragments. J Immunol 1979; 123:2144–9. PMID:489977
Akagaki Y, Inai S. Activation of the alternative complement pathway by the immune precipitate formed with F(ab′)2 fragment of human IgG antibody. Mol Immunol 1983; 20:1221–6. PMID:6419059 doi:10.1016/0161-5890(83)90146-3
Joiner KA, Goldman RC, Hammer CH et al. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab′)2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. J Immunol 1983; 131:2563–9. PMID:6355296
Terness P, Opelz G. Natural anti-immunoglobulin autoantibodies: Irrelevant by-products or immunoregulatory molecules? Int Arch Allergy Immunol 1998; 115:270–7. PMID:9566349 doi:10.1159/000069457
Terness PI, Navolan D, Dufter C et al. Immunosuppressive anti-immunoglobulin autoantibodies: Specificity, gene structure and function in health and disease. Cell Mol Biol 2002; 48:271–8. PMID:12030431
Kormeier LC, Ing JT, Mandy WJ. Specificity of antiglobulin factors in normal human serum reacting with enzyme digested gamma-G-globulin. J Immunol 1968; 100:612–21. PMID:4966843
Heimer R, Wolfe LD, Abruzzo JL. The specificity of antibodies to the F(ab′)2 fragment of human IgG. Arthritis Rheum 1985; 28:562–8. PMID:3873943 doi:10.1002/art.1780280516
Terness P, Kohl I, Hübener G et al. The natural human IgG anti-F(ab′)2 antibody recognizes a conformational IgG1 hinge epitope. J Immunol 1995; 154:6446–52. PMID:7539020
Fumia S, Goede JS, Fischler M et al. Human F(ab′)2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol Immunol 2008; 45:2951–61. PMID:18339427 doi:10.1016/j.molimm.2008.01.029
Yano S, Kaku S, Suzuki K et al. Natural antibodies against the immunoglobulin F(ab′)2 fragment cause elimination of antigens recognized by the F(ab′)2 from the circulation. Eur J Immunol 1995; 25:3128–33. PMID:7489753 doi:10.1002/eji.1830251121
Baici A, Knöpfel M, Fehr K et al. Kinetics of the different susceptibilities of the four human immunoglobulin G subclasses to proteolysis by human lysosomal elastase. Scand J Immunol 1980; 12:41–50. PMID:6902981 doi:10.1111/j.1365-3083.1980.tb00039.x
Donnelly SC, MacGregor I, Zamani A et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:1428–33. PMID:7735596
Gardinali M, Padalino P, Vesconi S et al. Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease. Arch Surg 1992; 127:1219–24. PMID:1417490
Konstan MW, Hilliard KA, Norvell TM et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150:448–54. PMID:8049828
Ryan MH, Petrone D, Nemeth JF et al. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 2008; 45:1837–46. PMID:18157932 doi:10.1016/j.molimm.2007.10.043
Dietrich H. Report on the experience in the treatment of septic diseases with Gamma-Venin. Dtsch Med J 1966; 17:709–10. PMID:4167085
Brezski RJ, Luongo JL, Petrone D et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 2008; 181:3183–92. PMID:18713989
Werdan K, Pilz G, Bujdoso O et al. Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study*. Crit Care Med 2007; 35:2693–701. PMID:18074471 doi:10.1097/01.CCM.0000295426.37471.79
Lutz HU, Stammler P, Jelezarova E et al. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88:184–93. PMID:8704173
Vani J, Elluru S, Negi VS et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008; 7:440–4. PMID:18558359 doi:10.1016/j.autrev.2008.04.011
Kambe M, Bessho R, Fujii M et al. Sivelestat reduces myocardial ischemia and reperfusion injury in rat hearts even when administered after onset of myocardial ischemia. Interact Cardiovasc Thorac Surg 2009; 8:629–34. PMID:19279053 doi: 10.1510/icvts.2008.195933
Toda Y, Takahashi T, Maeshima K et al. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Int J Mol Med 2007; 19:237–43. PMID: 17203197
Suda K, Takeuchi H, Hagiwara T et al. Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock 2010; 33:526–31. PMID:19953005
Okayama N, Kakihana Y, Setoguchi D et al. Clinical effects of aneutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome. J Anesth 2006; 20:6–10. PMID: 16421669 doi: 10.1007/s00540-005-0362-9
Hoshi K, Kurosawa S, Kato M et al. Sivelestat, a neutrophil elastase inhibitor, reduces mortality rate of critically ill patients. Tohoku J Exp Med 2005; 207:143–8. PMID:16141683 doi:10.1620/tjem.207.143
Togo S, Matsuo K, Ishibe A et al. Usefulness of a selective neutrophil elastase inhibitor (sivelestat) in septic ARDS patients after gastrointestinal surgery. Hepatogastroenterology 2008; 55:967–73. PMID: 18705309
Hagiwara S, Iwasaka H, Togo K et al. Aneutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1. Inflammation 2008; 31:227–34. PMID: 18536984 doi:10.1007/s10753-008-9069-z
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Lutz, H.U. (2012). How Immune Complexes from Certain IgG NAbs and Any F(ab′)2 Can Mediate Excessive Complement Activation. In: Lutz, H.U. (eds) Naturally Occurring Antibodies (NAbs). Advances in Experimental Medicine and Biology, vol 750. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3461-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3461-0_14
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3460-3
Online ISBN: 978-1-4614-3461-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)